PARP Inhibitor Resistance in Breast and Gynecological Cancer: Resistance Mechanisms and Combination Therapy Strategies

Overview

Journal Front Pharmacol

Date 2022 Sep 12

PMID 36091750

Authors

Nannan Wang

Yan Yang

Dongdong Jin

Zhenan Zhang

Ke Shen

Jing Yang

Huanhuan Chen

Xinyue Zhao

Li Yang

Huaiwu Lu

Affiliations

Soon will be listed here.

Abstract

Breast cancer and gynecological tumors seriously endanger women's physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the management of advanced disease still faces great challenges. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been clinically approved for breast and gynecological cancer patients, significantly improving their quality of life, especially of patients with BRCA1/2 mutations. However, drug resistance faced by PARPi therapy has hindered its clinical promotion. Therefore, developing new drug strategies to resensitize cancers affecting women to PARPi therapy is the direction of our future research. Currently, the effects of PARPi in combination with other drugs to overcome drug resistance are being studied. In this article, we review the mechanisms of PARPi resistance and summarize the current combination of clinical trials that can improve its resistance, with a view to identify the best clinical treatment to save the lives of patients.

Citing Articles

and Beyond: Impact on Therapeutic Choices Across Cancer.

Tan J, Zhang Z, Goh H, Ngeow J Cancers (Basel). 2025; 17(1.

PMID: 39796639 PMC: 11718952. DOI: 10.3390/cancers17010008.

Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a mutation.

Huang W, Meng H, Xu Y, Huang L, Lou G Oncol Lett. 2024; 29(2):67.

PMID: 39619421 PMC: 11605280. DOI: 10.3892/ol.2024.14813.

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.

Arun B, Couch F, Abraham J, Tung N, Fasching P Br J Cancer. 2024; 131(9):1400-1414.

PMID: 39215191 PMC: 11519381. DOI: 10.1038/s41416-024-02827-z.

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer.

Kulkarni S, Gajjar K, Madhusudan S Front Oncol. 2024; 14:1414112.

PMID: 39135999 PMC: 11317305. DOI: 10.3389/fonc.2024.1414112.

[F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology.

Ndlovu H, Lawal I, Mdanda S, Kgatle M, Mokoala K, Al-Ibraheem A J Clin Med. 2024; 13(12).

PMID: 38929955 PMC: 11204862. DOI: 10.3390/jcm13123426.

References

Simoneau A, Xiong R, Zou L . The cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells. Genes Dev. 2021; 35(17-18):1271-1289. PMC: 8415318. DOI: 10.1101/gad.348479.121. View

Yalon M, Tuval-Kochen L, Castel D, Moshe I, Mazal I, Cohen O . Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PLoS One. 2016; 11(5):e0155711. PMC: 4873128. DOI: 10.1371/journal.pone.0155711. View

Rondinelli B, Gogola E, Yucel H, Duarte A, van de Ven M, van der Sluijs R . EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017; 19(11):1371-1378. DOI: 10.1038/ncb3626. View

Grabarz A, Barascu A, Guirouilh-Barbat J, Lopez B . Initiation of DNA double strand break repair: signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end-joining. Am J Cancer Res. 2012; 2(3):249-68. PMC: 3365807. View

Clements K, Schleicher E, Thakar T, Hale A, Dhoonmoon A, Tolman N . Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nat Commun. 2020; 11(1):6118. PMC: 7704667. DOI: 10.1038/s41467-020-19961-w. View

Xu G, Chapman J, Brandsma I, Yuan J, Mistrik M, Bouwman P . REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015; 521(7553):541-544. PMC: 4671316. DOI: 10.1038/nature14328. View

Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S . ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int J Gynecol Cancer. 2021; 31(11):1471-1475. PMC: 8573414. DOI: 10.1136/ijgc-2021-002973. View

Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim Y, Gris-Oliver A . RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018; 29(5):1203-1210. PMC: 5961353. DOI: 10.1093/annonc/mdy099. View

Fumet J, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E . Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or.... BMC Cancer. 2020; 20(1):748. PMC: 7418426. DOI: 10.1186/s12885-020-07253-x. View

10.

Wang J, Zhang Y, Yuan L, Ren L, Zhang Y, Qi X . Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in -mutated -negative metastatic or advanced breast cancer: a network meta-analysis. Aging (Albany NY). 2020; 13(1):450-459. PMC: 7834995. DOI: 10.18632/aging.202152. View

11.

Linsley P, Greene J, Brady W, Bajorath J, Ledbetter J, Peach R . Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994; 1(9):793-801. DOI: 10.1016/s1074-7613(94)80021-9. View

12.

Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N . EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. Cancer Cell. 2020; 37(2):157-167.e6. PMC: 7155421. DOI: 10.1016/j.ccell.2019.12.015. View

13.

Hurley R, Wahner Hendrickson A, Visscher D, Ansell P, Harrell M, Wagner J . 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol Oncol. 2019; 153(1):127-134. PMC: 6430710. DOI: 10.1016/j.ygyno.2019.01.015. View

14.

Kanakkanthara A, Hou X, Ekstrom T, Zanfagnin V, Huehls A, Kelly R . Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Res. 2021; 82(2):307-319. PMC: 8770599. DOI: 10.1158/0008-5472.CAN-21-0732. View

15.

Waks A, Cohen O, Kochupurakkal B, Kim D, Dunn C, Buendia Buendia J . Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020; 31(5):590-598. PMC: 7946408. DOI: 10.1016/j.annonc.2020.02.008. View

16.

Schaaf L, Schwab M, Ulmer C, Heine S, Murdter T, Schmid J . Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Res. 2016; 76(10):2868-75. DOI: 10.1158/0008-5472.CAN-15-2908. View

17.

Locati M, Curtale G, Mantovani A . Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol. 2019; 15:123-147. PMC: 7176483. DOI: 10.1146/annurev-pathmechdis-012418-012718. View

18.

Rudin N, Haber J . Two alternative pathways of double-strand break repair that are kinetically separable and independently modulated. Mol Cell Biol. 1992; 12(3):1292-303. PMC: 369562. DOI: 10.1128/mcb.12.3.1292-1303.1992. View

19.

Kim J, Lee S, Choi J, Woo H, Xhemalce B, Miller K . PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells. Mol Cell. 2020; 80(2):327-344.e8. PMC: 7572766. DOI: 10.1016/j.molcel.2020.08.018. View

20.

C Grossman D, Curry S, Owens D, Barry M, Davidson K, Doubeni C . Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(6):588-594. DOI: 10.1001/jama.2017.21926. View